GeneDx is trading 4.02% down at $64.62, with no clear company announcement or other catalyst specifically explaining the October 12 decline in available reporting. - Earlier coverage cited investor concerns about proposed Medicare reimbursement changes for genetic tests, but did not establish them as the cause of this session’s move. - Major indexes are mixed, with no broad decline exceeding 0.5% in the same direction.